STANDARD BIOTOOLS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.44 USD | +3.39% |
|
-3.17% | +10.41% |
| Apr. 25 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
| Apr. 25 | Sector Update: Health Care | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 242.1 | 444.7 | 299.8 | 92.78 | 175.5 | 933.2 | - | - |
| Enterprise Value (EV) 1 | 237.3 | 430.4 | 299.8 | 92.78 | 175.5 | 933.2 | 933.2 | 933.2 |
| P/E ratio | -3.59 x | -8.11 x | -5.03 x | -0.48 x | -2.35 x | -5.67 x | -13.6 x | 122 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.06 x | 3.22 x | 2.3 x | - | 1.65 x | 4.64 x | 4.02 x | 3.36 x |
| EV / Revenue | 2.06 x | 3.22 x | 2.3 x | - | 1.65 x | 4.64 x | 4.02 x | 3.36 x |
| EV / EBITDA | -5.13 x | -9.46 x | -4.7 x | - | -5.06 x | -8.45 x | -21.1 x | 29 x |
| EV / FCF | -4.72 x | - | - | - | -3.8 x | -7.91 x | -16.4 x | 73.5 x |
| FCF Yield | -21.2% | - | - | - | -26.3% | -12.6% | -6.11% | 1.36% |
| Price to Book | 1.51 x | 3.22 x | - | - | -1.18 x | 1.83 x | 2.03 x | 1.92 x |
| Nbr of stocks (in thousands) | 69,565 | 74,119 | 76,486 | 79,296 | 79,395 | 382,461 | - | - |
| Reference price 2 | 3.480 | 6.000 | 3.920 | 1.170 | 2.210 | 2.440 | 2.440 | 2.440 |
| Announcement Date | 2/10/20 | 2/10/21 | 2/17/22 | 2/14/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 117.2 | 138.1 | 130.6 | - | 106.3 | 201 | 232.2 | 277.5 |
| EBITDA 1 | -47.23 | -47.02 | -63.81 | - | -34.66 | -110.5 | -44.17 | 32.2 |
| EBIT 1 | -51.84 | -51.04 | -67.46 | - | -76.6 | -154.6 | -85.95 | -23.2 |
| Operating Margin | -44.22% | -36.94% | -51.66% | - | -72.03% | -76.93% | -37.02% | -8.36% |
| Earnings before Tax (EBT) 1 | -66.7 | -54.1 | -63.66 | - | -74.2 | -161.3 | -69.4 | 9 |
| Net income 1 | -64.79 | -53.02 | -59.24 | -190.1 | -74.66 | -161.3 | -69.4 | 9 |
| Net margin | -55.26% | -38.38% | -45.36% | - | -70.21% | -80.26% | -29.89% | 3.24% |
| EPS 2 | -0.9700 | -0.7400 | -0.7800 | -2.430 | -0.9400 | -0.4300 | -0.1800 | 0.0200 |
| Free Cash Flow 1 | -51.32 | - | - | - | -46.12 | -118 | -57.05 | 12.7 |
| FCF margin | -43.77% | - | - | - | -43.37% | -58.74% | -24.57% | 4.58% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 39.44% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 141.11% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/10/20 | 2/10/21 | 2/17/22 | 2/14/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 28.5 | 38.26 | 26.5 | - | 27.67 | 25.37 | 28.19 | 46 | 48.2 | 51.57 | 55.27 | 51.4 |
| EBITDA 1 | -18.72 | -10.35 | - | - | -8.369 | -10.14 | -7.525 | -34.57 | -31.83 | -24.97 | -19.07 | -16.8 |
| EBIT 1 | -19.61 | -11.26 | - | - | -17.45 | -21.17 | -21.39 | -46.9 | -42.9 | -35.5 | -29.3 | -32.4 |
| Operating Margin | -68.8% | -29.42% | - | - | -63.07% | -83.46% | -75.87% | -101.96% | -89% | -68.84% | -53.02% | -63.04% |
| Earnings before Tax (EBT) 1 | -15.26 | -10.24 | - | - | -16.74 | -20.95 | -19.94 | -45.5 | -43.6 | -38.5 | -33.8 | - |
| Net income 1 | -13.84 | -9.429 | - | -16.84 | -17.04 | -21 | -19.78 | -45.5 | -43.6 | -38.6 | -33.8 | - |
| Net margin | -48.57% | -24.64% | - | - | -61.59% | -82.77% | -70.16% | -98.91% | -90.46% | -74.85% | -61.16% | - |
| EPS 2 | -0.1800 | -0.1200 | - | -0.2100 | -0.2200 | -0.2700 | -0.2500 | -0.1200 | -0.1100 | -0.1000 | -0.0900 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/17/22 | 5/5/22 | 5/9/23 | 8/8/23 | 11/7/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 4.82 | 14.3 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -51.3 | - | - | - | -46.1 | -118 | -57.1 | 12.7 |
| ROE (net income / shareholders' equity) | -57.4% | -14.9% | - | - | - | -45.9% | -13.4% | 1.8% |
| ROA (Net income/ Total Assets) | -22.8% | - | - | - | -20.9% | -30.1% | -9.5% | 1.3% |
| Assets 1 | 284.2 | - | - | - | 356.7 | 535.9 | 730.5 | 692.3 |
| Book Value Per Share 2 | 2.300 | 1.870 | - | - | -1.870 | 1.330 | 1.200 | 1.270 |
| Cash Flow per Share 2 | -0.7300 | - | - | - | -0.5500 | -0.3400 | -0.1100 | 0.0900 |
| Capex 1 | 2.53 | 12.7 | - | - | 2.83 | 5 | 5.27 | 7 |
| Capex / Sales | 2.16% | 9.21% | - | - | 2.66% | 2.49% | 2.27% | 2.52% |
| Announcement Date | 2/10/20 | 2/10/21 | 2/17/22 | 2/14/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.44
USD
Average target price
3.583
USD
Spread / Average Target
+46.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.41% | 933M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- LAB Stock
- Financials Standard BioTools Inc.
